Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mary Veremis Ley

Dermatology Clinton Township, MI Doctor of Osteopathy

NPI 1235133703 CMS profile 282313

43900 Garfield Rd, Ste 100, Clinton Township, MI 48038

Open in the dashboard

General payments

$5,796

143 records reported · program years 2019–2025

Research payments

$1,169

Paid to them · 6 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$329,905 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Mary Veremis Ley of Clinton Township, MI is reported in the CMS Open Payments database as having received $5,796 across 143 general payments and $1,169 in research payments paid to them. Separately, studies naming them as principal investigator received $329,905 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 72nd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,686 40
2024 General $935 33
2024 Research $1,169 6
2023 General $1,781 18
2022 General $160 6
2021 General $168 8
2020 General $304 14
2019 General $762 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mary Veremis Ley
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Mary Veremis Ley were reported at $1,686. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Mary Veremis Ley Dermatology median Middle half National median
2019 $762 $454 $129–$1,240 $163
2020 $304 $235 $81–$756 $114
2021 $168 $377 $108–$1,108 $132
2022 $160 $514 $143–$1,391 $149
2023 $1,781 $607 $159–$1,674 $160
2024 $935 $751 $204–$1,903 $164
2025 $1,686 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. LEO Pharma Inc. $1,467 10 payments
  2. AbbVie, Inc. $603 24 payments
  3. Genzyme Corporation $602 33 payments
  4. UCB, Inc. $593 9 payments
  5. Janssen Biotech, Inc. $395 8 payments
  6. Allergan Inc. $375 7 payments
  7. Regeneron Healthcare Solutions, Inc. $334 9 payments
  8. Sanofi-Aventis U.S. LLC $214 3 payments
  9. Dermavant Sciences, Inc. $182 5 payments
  10. Musculoskeletal Transplant Foundation Inc. $165 1 payment
  11. Other $865 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,169 136 payments
  2. Consulting Fee $1,240 1 payment
  3. Education $325 5 payments
  4. Travel and Lodging $63 1 payment
Products named General payments · program years 2019–2025
  1. ADBRY $1,300 6 payments
  2. DUPIXENT Immunology $628 25 payments
  3. Bimzelx $593 9 payments
  4. TREMFYA $395 8 payments
  5. DUPIXENT Inflammation And Immunology $309 8 payments
  6. VTAMA $309 6 payments
  7. DUPIXENT Immunology $168 10 payments
  8. BOTOX COSMETIC $148 3 payments
  9. LITFULO $144 4 payments
  10. ANZUPGO $140 3 payments
  11. Other $1,281 64 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. AbbVie, Inc. $1,169 6 payments

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,349

Median for Dermatology: 534

Drug cost

$31,457

Median for Dermatology: $67,151

Branded share of claims

2.2%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fluorouracil Generic 104 $6,780
Clobetasol Propionate Generic 145 $3,956
Azelaic Acid Generic 24 $2,170
Econazole Nitrate Generic 88 $2,131
Hydrocortisone Generic 108 $1,845
Tretinoin Generic 21 $1,834
Metronidazole Generic 50 $1,597
Clindamycin Phosphate Generic 59 $1,431
Mupirocin Generic 193 $1,215
Fluticasone Propionate Generic 86 $1,179

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 71 billing codes

Paid by Medicare

$177,807

Of which drugs: $2,872

Medicare patients

743

Average age 75

Services billed

3,752

523 women, 220 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Ischemic heart disease 26%
Diabetes 25%
Chronic kidney disease 22%
Osteoporosis 16%
Atrial fibrillation 15%
Cancer 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 36 58 $44

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $173
  • Regeneron Healthcare Solutions, Inc. $46
$219 — —
TREMFYA
  • Janssen Biotech, Inc. $134
$134 — —
BOTOX
  • AbbVie, Inc. $100
$100 — —
VTAMA
  • Dermavant Sciences, Inc. $99
$99 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $43
$43 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

149 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record